Ep. 1: EyeCon 2022: Join the fun in-person at Marco Island

Video

Optometry Times®' EyeCon 2022 co-chairs Kelly K. Nichols, OD, MPH, PhD, FAAO, and A. Paul Chous, MA, OD, FAAO, sat down with Ben Casella, OD, FAAO, chief optometric editor for Optometry Times® to chat all-things EyeCon 2022.

Save the dates for the Optometry Times® Eyecon 2022 meeting.

Friday, December 16, and Saturday, December 17, will see optometrists convening in Marco Island, Florida, to discuss the latest advances in diagnostic tools and treatments and share their experiences in this southwest Florida subtropical paradise at the JW Marriott Marco Island Beach Resort.

Optometry Times®' EyeCon 2022 co-chairs Kelly K. Nichols, OD, MPH, PhD, FAAO, dean of the University of Alabama at Birmingham School of Optometry in Birmingham, Alabama, and A. Paul Chous, MA, OD, FAAO, a diabetes eye care specialist in Tacoma, Washington, sat down with Ben Casella, OD, FAAO, chief optometric editor for Optometry Times® to chat all-things EyeCon 2022.

This transcript has been lightly edited for clarity:

Casella:

Hey, what's up everybody, Ben Casella, your chief optometric editor for Optometry Times®.

I have the pleasure today to be joined by my two friends, Dr. Kelly Nichols and Dr. Paul Chous. Thank you both for making time for us. These are your co-chairs of Optometry Times® EyeCon 2022.

Related: Optometry Times®' Eyecon 2022 kicks off this December

I'm excited: Marco Island, it sounds lovely; I'm gonna bring a track suit and a shuffleboard paddle. I'm ready to go. But you guys have a few high points that you want us to be acutely aware of before we all run off and register for the meeting. And I appreciate you guys. Dr. Nichols, I'm going to start with you.

Nichols:

We're super excited to have this meeting in-person this year. Last year was our first year our inaugural year and it was virtual was a fantastic lineup of speakers and the panel was panel presentation. So it was really fabulous.

This year we have the good fortune of going to Marco Island so who doesn't love great CEE in a beautiful location. What do you think, Paul?

Chous:

Yeah, Kelly. I'm thrilled to be doing this again with you and it's gonna be great to do it in person.

Related: Q&A: EyeCon sneak peek with Dr Bloomenstein

I looked up the average temperature in Marco Island in December is 75 degrees. That sounds pretty nice for mid December to me. I'm hoping we'll draw some folks from the bitter Arctic North who will want to come down and have a little r&r before the holiday season gets so crazy.

Registration for the program is currently open. Get registered now!

Recent Videos
EnVision Summit Cochair Cecelia Koetting, OD, FAAO, Dipl ABO, says that attendees should get ready for more discussion-based panels at this year's conference.
Bonnie An Henderson in an interview for the EnVision Summit
EnVision Summit cofounder and program chair Dr Bonnie Henderson chats about collaborative eye care
Bonnie An Henderson in an interview for the EnVision Summit
EnVision Summit Co-chairs Sherrol Reynolds, OD, FAAO; Katie Rachon, OD, FAAO, Dipl ABO; Jessica Steen, OD, FAAO, Dipl ABO; and Cecelia Koetting, OD, FAAO, Dipl ABO; express excitement for the upcoming conference and why optometrists should attend.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
© 2025 MJH Life Sciences

All rights reserved.